SubHero Banner
Text

Keytruda® (pembrolizumab) – Expanded indication

May 5, 2021 - Merck announced the FDA approval of Keytruda (pembrolizumab), in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Download PDF